Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 411

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 411
---
 In October 2024, the Parent, at the sole discretion of the shareholders of the Parent, entered into Deferred Share Right Agreements (“DSRs”) with three key employees of Heritas Argentina (each a “Key Employee”). These agreements were structured to incentivize and retain critical talent identified as essential for OmnigenicsAI and Heritas Argentina’s success following the Closing. Under the terms of these DSRs, (i) each employee will receive a deferred share grant of 30,000shares of the Parent, for a total of 90,000shares to be granted; (ii) the shares will vest and be transferred one year after the Closing (the “Vesting Date”), provided the Key Employee remains employed with the Parent, or its affiliates, including OmnigenicsAI and Heritas Argentina; and in the event of resignation or termination for cause before the Vesting Date, the shares will be forfeited. Conversely, in the case of termination without cause, the rights will vest immediately. No additional share -basedincentives have been provided. Share Option Plan The Company has no share option plan in place for employees. 208 OmnigenicsAI Management’s Discussion and Analysis of
Financial Condition and Results of Operations The following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of OmnigenicsAI’s results of operations and financial condition. This discussion and analysis should be read together with the section of this proxy statement / prospectus entitled “Selected Historical Financial Information of OmnigenicsAI”, the audited combined financial statements, and related notes of OmnigenicsAI that are included elsewhere in this proxy statement / prospectus, which include financial data for the year ended June 30, 2024 and as of June 30, 2024. This discussion and analysis should also be read together with the unaudited interim condensed combined financial statements for the six -month period ended December 31, 2024, the section of this proxy statement / prospectus entitled “Business of the Company and Information About the Company” and the unaudited pro forma combined consolidated financial information for the year ended June 30, 2024, and as of and for the six -month period ended December 31, 2024 in the section of this proxy statement / prospectus entitled “Unaudited Pro Forma Combined Financial Information.” In addition to historical financial information, this discussion and analysis contains forward -looking statements based upon current expectations that involve risks, uncertainties and assumptions. See the section